NCT04598906 is a NA clinical trial of Virtual environment rehabilitation in Schizophrenia, sponsored by National Institute of Mental Health, Czech Republic.

Who is sponsoring NCT04598906?

NCT04598906 is sponsored by National Institute of Mental Health, Czech Republic.

What drugs are being tested in NCT04598906?

Interventions in NCT04598906: Virtual environment rehabilitation, Paper-pencil rehabilitation.

What condition does NCT04598906 study?

NCT04598906 studies Schizophrenia, Depression, Cognitive Impairment.

Is NCT04598906 still recruiting?

NCT04598906 is currently completed. Last updated 2 March 2021.

Last reviewed 2021-03-02 · How we verify

NCT04598906

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ecologically Valid Virtual Tasks vs Paper-pencil Methods in Cognitive Rehabilitation in Patients With Schizophrenia and Depression

Completed NA Last updated 2 March 2021

What this trial tests

NA trial testing Virtual environment rehabilitation in Schizophrenia in 35 participants. Completed in 1 January 2021.

Timeline

1 September 2019

Primary endpoint
1 January 2021

1 January 2021

Quick facts

Lead sponsor	National Institute of Mental Health, Czech Republic
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	35
Start date	1 September 2019
Primary completion	1 January 2021
Estimated completion	1 January 2021
Sites	1 location across Czechia

Drugs / interventions tested

Virtual environment rehabilitation
Paper-pencil rehabilitation

Conditions studied

Schizophrenia — all drugs for Schizophrenia →
Depression — all drugs for Depression →
Cognitive Impairment — all drugs for Cognitive Impairment →

Sponsor

National Institute of Mental Health, Czech Republic

Who can join

Adults 18 to 60, any sex, with Schizophrenia or Depression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Schizophrenia is heterogeneous and often disabling a disease that affects 1% of the population. Current psychopharmacological treatment significantly eliminates the presence of positive symptoms (especially delusions and hallucinations) and partly also negative symptoms (social withdrawal or abulia). In contrast, the cognitive deficits associated both with schizophrenia and depression are only limitedly influenced by pharmacological treatment.The cognitive impairment represents an important part of schizophrenia symptomatology and it has a severe negative impact on patients' quality of life. In depression is the impairment milder but still significantly contributes to patients' daily functioning. The profound deficit was repeatedly documented in the area of declarative and working memory. In this study, we study the effectiveness of virtual environment rehabilitation program focused on declarative memory, working memory and attention in comparison to standard paper-pencil rehabilitation led by an occupational therapist.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Schizophrenia

Currently open trials in the same condition.

NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting

Other National Institute of Mental Health, Czech Republic trials

Trials by the same sponsor.

NCT07064629 — Training of Relaxation Breathing in Virtual Reality Using Biofeedback: Comparison Study · NA · enrolling by invitation
NCT06915883 — Experiential and Relaxation Virtual Reality as a Tool for Easing Anxiety in Seriously Ill Children · NA · recruiting
NCT07206199 — Virtual Reality Exposure Therapy for Obsessive-Compulsive Disorder: Outpatients Trial · NA · recruiting
NCT07245134 — Virtual Reality Exposure Therapy for Obsessive-Compulsive Disorder: A Randomized Controlled Trial in Inpatients · NA · recruiting
NCT04876144 — Kogito: App to Reduce Perinatal Psychosocial Stress · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04598906 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Institute of Mental Health, Czech Republic
Last refreshed: 2 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04598906.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing